# Transcript: Renaissance in Obesity Treatment Innovation **Date:** March 17, 2026 · 10:00 PM **Session:** [Renaissance in Obesity Treatment Innovation](/sessions/2026-03-17/pp1162883-renaissance-in-obesity-treatment-innovation) ## Summary This SXSW session explored the "Renaissance in Obesity Treatment Innovation," highlighting the shift from viewing obesity as a personal failing to recognizing it as a complex chronic disease driven by biology and genetics. Panelists discussed new medical advancements, including genetic-based therapies and GLP-1s, that offer significant weight reduction and health improvements, emphasizing the importance of body composition over mere weight loss. The discussion also covered the critical need for personalized, wrap-around care, addressing societal biases, and advocating for systemic changes in healthcare access and insurance coverage for obesity treatments. ## Topics `obesity treatment` · `medical innovation` · `chronic disease` · `genetics` · `glp-1s` · `body composition` · `healthcare access` · `patient advocacy` · `bias` · `personalized medicine` · `weight management` · `public health` ## Key Takeaways 1. Obesity should be recognized and treated as a chronic disease, not a personal failing, with treatment focusing on health improvement and body composition rather than just weight loss. 2. New medical innovations, including GLP-1s and genetic-based therapies, offer significantly more effective treatment options, but require comprehensive, personalized care that goes beyond medication. 3. Addressing societal bias and stigma around obesity is crucial for improving patient care and encouraging individuals to seek treatment without shame. 4. Systemic changes are needed in healthcare, including insurance coverage and policy, to ensure equitable access to effective obesity treatments and integrate them into standard care. 5. Future advancements will likely focus on personalized medicine, maintenance therapies, and interventions that consider individual biology and lifestyle for long-term health outcomes. ## Full Transcript Wave Life Sciences is developing a genetic-based therapy for obesity, focusing on reducing a protein responsible for fat storage. This innovation aims to reduce harmful visceral fat while preserving lean muscle mass, offering a new approach to obesity treatment grounded in human genetics. The company is excited to advance this program, which targets the biological mechanisms of fat accumulation. Dr. Angela Fitch, Chief Medical Officer of KnownWell, leads a tech-enabled healthcare company providing primary and obesity medicine to 22,000 patients across five states and virtually. She highlights the significance of Medicare beginning to cover obesity treatments, a major shift after years of advocacy. Dr. Fitch, board-certified in obesity medicine since 2012, has witnessed the evolution of this field. John McCloskey, who manages the Obesity Action Coalition, shares his personal journey of living with obesity for 34 years, undergoing numerous behavioral programs and medications. He emphasizes that his motivation for treatment is health and quality of life, not just weight loss, aiming to maintain an active lifestyle into old age. The recent innovations offer remarkable success, but he acknowledges the ongoing need for new medicines as bodies and situations change. The panel discusses what is really working in obesity treatment, noting the significant impact of newer innovations. Historically, obesity was blamed on gluttony and sloth, with lifestyle interventions alone yielding only 3-5% weight loss for most. Today, advanced treatments enable 70% of individuals to achieve 20% weight loss, a radical improvement resulting from 20 years and billions in investment, marking a true renaissance in care. There is a crucial shift in narrative from weight loss to health improvement and body composition, focusing on reducing harmful fat while preserving lean muscle mass. Panelists advocate for measuring health outcomes beyond just pounds on a scale, using tools like DEXA scans and 3D anthropometry. This change in perspective emphasizes being "leaner, not lighter," and recognizing muscle as a vital endocrine organ. The discussion highlights the pervasive societal bias and judgment against individuals with obesity, even from healthcare professionals and family members. This stigma, often fueled by simplistic views like "eat less, move more," ignores the complex genetic and biological underpinnings of the disease. Panelists stress the importance of recognizing obesity as a non-choice, chronic condition to enable effective treatment and reduce shame. A major challenge is the "off-ramp" mentality for obesity medications, unlike other chronic diseases where long-term treatment is accepted. This stems from old diet culture, where weight loss is followed by inevitable regain, often with more pounds. The need to break this cycle and accept long-term treatment, similar to blood pressure medication, is crucial for sustained health benefits. The concept of weight cycling, where stopping treatment leads to regaining more fat and further health complications, underscores the need for continuous care. New genetic-based therapies aim to not only induce fat loss but also curtail rebound weight gain, offering a potential once or twice-a-year maintenance option. This evolution of care, moving beyond a "mission accomplished" mindset, is vital for long-term success, much like advancements in cancer treatment. The intersection of science and culture is creating momentum, shifting the conversation from scale numbers to quality of life and longevity. This is particularly relevant in women's health, as menopause often leads to fat gain, not muscle. While women are often the primary seekers of obesity care, driven by cultural desires for thinness, the focus should be on health and well-being. Personalization of care is identified as the next frontier, moving beyond a trial-and-error approach to tailored therapies based on individual phenotype and genotype. This requires a comprehensive "wrap-around care" model, integrating behavioral therapy, medicines, surgery, and devices, rather than generic advice. The innovation in medicine has outpaced the healthcare system's ability to deliver this personalized support effectively. A critical systemic issue is that obesity is not considered an essential health benefit in the US, making access to care elective and often uncovered by insurance. This leads to situations where employers drop coverage due to high costs, despite obesity being a prevalent chronic disease. Advocacy efforts are focused on changing this, with hope for Medicare and Medicaid to cover obesity medicines and prove their long-term value and cost-effectiveness. New data, such as from the UK Biobank, demonstrates that treating obesity at its root by reducing harmful visceral fat leads to significant health improvements, including reduced inflammation, lower lipid levels, and better cardiovascular and diabetes outcomes. This evidence makes it easier to advocate for coverage with payers, showing that investing in obesity treatment can reduce overall healthcare costs. The global prevalence of obesity, even in regions with diverse diets, underscores its biological rather than purely caloric drivers. The panel discusses the potential for obesity medicines to impact the food system, as consumer demand shifts towards healthier choices when individuals are on effective treatments. Walmart data showing healthier food baskets for those on these medicines suggests a powerful, unexpected driver for change in food manufacturing. This could also transform the healthcare system by shifting focus from expensive procedures to prevention and addressing drug pricing issues. Scientific advances are expected to foster greater empathy by revealing the complex root causes of obesity and individual differences. Understanding that obesity is not solely driven by caloric consumption, but by biological mechanisms that accumulate inflammatory fat, removes blame from the individual. This scientific understanding is crucial for shifting the narrative from personal failing to a treatable disease. Progress is already visible as clinicians increasingly discuss GLP-1s, shifting the conversation from "eat less, move more" to biology-based treatments. However, internalized bias and self-blame still prevent many from seeking care, highlighting the need for research into how people can forgive themselves. The goal is to move towards personalized care, recognizing different types of obesity, much like targeted cancer treatments, supported by AI and data synthesis. The drug discovery process must remain patient-centric, prioritizing convenience, safety, and tolerability. Innovations like once or twice-a-year dosing, similar to a flu shot, could significantly improve adherence and long-term outcomes. Wave's genetic-based therapy, for example, avoids central nervous system and GI side effects by targeting fat storage directly, making it suitable for combination and maintenance therapy. It is crucial to distinguish between weight loss and weight maintenance, as patients often struggle with the latter and the ingrained "diet culture" mentality. While reducing "food noise" can be powerful, patients need guidance to ensure adequate nutrition and avoid turning off appetite entirely. Good clinical care is essential to manage dosing, prevent rapid escalation, and ensure patients receive customized advice for long-term health, rather than just chasing a number on the scale. Responsible drug development, backed by billions in investment and rigorous studies, is critical for ensuring efficacy, safety, and long-term tolerability. Tightly regulated manufacturing processes guarantee that what is in the medicine is what was studied, preventing issues like impurities that render treatments ineffective. This commitment to quality and regulation is paramount for therapies that patients may take for a lifetime. Future research should focus on developing tools to help individuals overcome internalized bias and self-blame, which currently deter many from seeking care. Personalization of treatment, leveraging genetics and digital technology, is another key area to move beyond trial-and-error. Culturally, there is a need to shift public discourse, especially in media and public service announcements, to a non-stigmatizing view of obesity as a chronic disease. While some attribute obesity issues solely to hyper-capitalism in the US, obesity is a global pandemic affecting a billion people worldwide, including regions with different dietary patterns. The impact on global healthcare systems is universal, driving the development of obesity medicines across continents. The data from global clinical trials consistently shows that reducing harmful fat improves health outcomes, regardless of geographical or economic context. --- *Source: stt · Language: en · Model: google-vertex/gemini-2.5-flash* [← Back to session](/sessions/2026-03-17/pp1162883-renaissance-in-obesity-treatment-innovation)